Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Por:
Smith, A, Armstrong, AW, Elewski, B, Rich, P, Augustin, M, Carrascosa, JM, Vender, R, Lambert, J, Pinto, JML, Hoepken, B, Kavanagh, S and Puig, L
Publicada:
1 jun 2025
Resumen:
Filiaciones:
Smith, A:
St Vincents Hosp, Greystanes, NSW, Australia
Armstrong, AW:
Keck Sch Med USC, Dermatol, Los Angeles, CA USA
Elewski, B:
Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH USA
Rich, P:
Icahn Sch Med Mt Sinai, New York, NY USA
Augustin, M:
Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain
Vender, R:
Dermatrials Res Inc, Hamilton, ON, Canada
Lambert, J:
UCB Pharma, Colombes, France
Pinto, JML:
UCB Pharma, Madrid, Spain
Hoepken, B:
UCB Pharma, Monheim, Germany
Kavanagh, S:
UCB, Morrisville, NC USA
Puig, L:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
|